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ABSTRACT
Background: Activated PI3K/AKT/mTOR pathway frequently occurs in metastatic 
or recurrent cervical carcinomas. However, the clinical benefits of matched therapy, a 
therapeutic approach targeting a specific mutational abnormality, have not yet been 
established.
Methods: We analyzed the outcomes of patients with metastatic or recurrent 
cervical carcinomas who had a test for PIK3CA mutation and/or PTEN loss/mutation, 
and received ≥1 phase I therapeutic regimen between January 2006 and June 2013.
Results: Patients with adenocarcinoma had fewer PIK3CA mutations (14%), and 
survived longer (median, 14.2 months) than those with squamous cell carcinoma 
(48% and 7.2 months; p = 0.016, and 0.001, respectively). Matched therapy targeting 
the activated PI3K/AKT/mTOR pathway led to a favorable rate of SD ≥ 6 months/CR/
PR (53%) and significantly longer progression-free survival (median, 6.0 months) 
than non-matched therapy (11% and 1.5 months; p = 0.08 and 0.026; respectively). 
In patients with squamous cell carcinoma of the cervix, the presence of PIK3CA 
mutations was associated with a significantly longer overall survival (median, 
9.4 months) than the absence of PIK3CA mutations (median, 4.2 months; p = 0.019).
Conclusions: Matched therapy targeting the activated PI3K/AKT/mTOR pathway 
provided meaningful clinical benefits. Thus, further evaluation of PI3K/AKT/mTOR 
pathway targeted therapy is warranted, especially in metastatic or recurrent 
squamous cell carcinoma.
INTRODUCTION
Cancer of the uterine cervix is one of the most 
common gynecologic malignancies and causes of death 
worldwide [1]. In the United States, more than 12,000 
women were diagnosed with cervical cancer in 2013, 
and more than 4,000 patients died from this disease [2]. 
Squamous cell carcinoma and adenocarcinoma account for 
about 95% of all cervical cancers [3]. Most patients who 
are diagnosed with early-stage disease have a high rate 
of long-term survival after they have undergone curative 
surgical resection and/or chemoradiotherapy [4, 5]. 
Patients with recurrent or metastatic cervical cancers 
who are not amenable to radical local excision or curative 
chemoradiotherapy, have a poor prognosis [6, 7]. Palliative 
systemic therapies such as platinum-based doublets plus 
an anti-angiogenic agent as the standard of care for first-
line treatment yield modest survival gains of 3.7 months 
[8–10]. Subsequent conventional chemotherapeutic 
regimens result in increased toxicity with limited clinical 
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benefit [11]. The overall poor prognosis of these patients 
warrants the urgency for the development of novel 
therapeutic regimens [12, 13].
There are three classes of phosphoinositide 3-kinase 
(PI3K) isoforms [14]. Class I PI3Ks are heterodimeric lipid 
kinases composed of the p110 catalytic subunit and the 
p85 regulatory subunit. Three major p110 isoforms have 
been described: p110α (PIK3CA), p110β (PIK3CB), and 
p110δ (PIK3CD) [15, 16]. PI3K and PTEN counterpoise 
each other on conversion between phosphatidyl-inositol-
4-5-bisphosphate (PIP2) and phosphatidyl-inositol-3, 4, 
5-trisphosphate (PIP3) [17, 18]. Upon activation through 
either PIK3CA mutation or PTEN loss/mutation, PI3K 
phosphorylates PIP2 to PIP3, which facilitates recruitment 
and activation of AKT to initiate a cascade of downstream 
signaling events including the mTOR complex, a major 
downstream pathway [16]. Therefore, a regimen including 
a PI3K inhibitor and/or an mTOR inhibitor can be utilized 
to target PIK3CA mutation and/or PTEN loss/mutation-
mediated activated PI3K/AKT/mTOR pathway [19]. 
This strategy is defined as matched therapy: a therapeutic 
regimen including an agent (either as a single agent or 
as a part of a combination regimen) that is known to 
directly inhibit a specific mutation, and/or to inhibit its 
key downstream pathways, such as treatment with a 
PI3K inhibitor, an mTOR inhibitor, or these agent-based 
regimens for a cancer patient carrying a PIK3CA mutation 
and/or PTEN loss/mutation [20].
Our previous study and others have documented 
that the activated PI3K/AKT/mTOR pathway is frequently 
identified in patients with metastatic or recurrent cervical 
cancers [21–25]. We hypothesized that cervix cancer 
patients with aberrations in this pathway would achieve 
clinical benefit (defined as objective response and 
prolonged stable disease) when treated with PI3K/AKT/
mTOR pathway targeted agents. In this article, we further 
our previous study by limiting patients who only have 
either squamous cell carcinoma or adenocarcinoma of 
the cervix in order to reach definitive conclusions, which 
will be applied to facilitate future drug development by 
choosing appropriate therapeutic regimens for appropriate 
cancer patients. Herein we document a clear observation 
of antitumor responses with acceptable toxicity from 
PI3K/AKT/mTOR matched therapy, representing an 
important new therapeutic strategy for a patient population 
possessing limited treatment options.
PATIENTS AND METHODS
Patient selection
Consecutive patients with metastatic or recurrent 
cervical carcinoma (either squamous cell carcinoma or 
adenocarcinoma) who were referred to the Department of 
Investigational Cancer Therapeutics (A Phase I Clinical 
Trials Program) at MD Anderson between January 1, 2006, 
and June 30, 2013, had a test for PIK3CA mutation and/or 
PTEN loss/mutation in a Clinical Laboratory Improvement 
Amendments-certified molecular diagnostic laboratory, 
and received treatment in at least one phase I clinical 
trial, were evaluated. Follow-up was defined as the time 
of the initial office visit after the patient was referred to 
the phase I clinic until death or February 28, 2014. This 
study was conducted in accordance with MD Anderson’s 
Institutional Review Board guidelines.
Data collection
Two individuals independently reviewed patients’ 
electronic medical records at MD Anderson and 
crosschecked the collected data. Clinical information that 
was collected included race, prior treatment history (e.g., 
surgery, radiation therapy, and chemotherapy), date of 
birth, Eastern Cooperative Oncology Group performance 
status at the initial phase I clinic visit, mutation profiling 
of the tumor specimen including PIK3CA mutation and/or 
PTEN loss/mutation status, phase I clinical trial therapies, 
and clinical outcomes: severe adverse event (SAEs), 
progression-free survival (PFS), overall survival (OS), and 
objective responses including complete remission (CR), 
partial response (PR), and stable disease for 6 months or 
longer (SD ≥ 6months).
SAEs were defined as toxic effects that were grade 3 
or higher according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events v3.0 
or v4.0 (http://ctep.cancer.gov/reporting/ctc.html) [26]. 
Clinical objective responses were evaluated according to 
the Response Evaluation Criteria in Solid Tumors version 
1.0 or 1.1 per individual study protocols [27, 28]. PFS was 
defined as the interval from the date of initial treatment to 
the first objective documentation of disease progression, 
the time of death if it occurred, or the last date of contact 
on February 28, 2014, at which time the patients’ data 
were censored. OS was estimated from the date of the 
initial phase I clinical trial therapy to death or the last 
date of contact on February 28, 2014, at which time the 
patients’ data were censored.
Enrollment of an eligible patient into a specific 
phase I trial depended on the availability of the phase I 
trial at the time of presentation and the preference of the 
treating physician according to good clinical practice. If a 
phase I trial was unsuccessful, another available phase I 
trial was introduced as long as a patient was eligible and 
willing to participate.
Statistical analyses
Categorical data were described using contingency 
tables. Continuously scaled measures were summarized 
with descriptive statistical measures (i.e., the median with 
the range), whereas PFS and OS rates were estimated 
using the Kaplan-Meier method. Patients who were 
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still alive at the time of data analysis were censored at 
that time. Fisher’s exact test was used to assess the 
associations between categorical variables and mutation 
status. Statistical inferences were based on two-sided tests 
at a significance level of p < 0.05. Statistical analyses were 
carried out using SPSS Statistics version 22 (IBM Inc., 
Armonk, NY).
RESULTS
Study population
Fifty-five consecutive patients with metastatic 
or recurrent adenocarcinoma (n = 24) or squamous cell 
carcinoma (n = 31) who had a test for PIK3CA mutation 
and/or PTEN loss/mutation and underwent treatment in at 
least one phase I clinical trial in the Phase I Clinical Trials 
Program were included in this study. Patient characteristics 
and molecular profiling are listed in Table 1. All patients 
had received at least one prior systemic chemotherapeutic 
regimen for metastatic or recurrent disease (median 2 
regimens, range 1 to 4) and underwent molecular 
marker studies in a Clinical Laboratory Improvement 
Amendments-certified molecular diagnostic laboratory.
Twenty-two patients were found to harbor PIK3CA 
mutations and/or PTEN loss: 17 (33%) of 51 tested 
patients with PIK3CA aberrations (E545K = 8, E542K = 4, 
H1047L = 1, H1047R = 1, E545K and D549H = 1, 
Table 1: Patient characteristics and molecular profiles.
Patient characteristics Adenocarcinoma Squamous cell carcinoma Total patients
(n = 24) (n = 31) (n = 55)
Age, years
 Median (range) 51 (27–67) 42 (25–69) 46 (25–69)
Race
 White 17 19 36
 African American 2 5 7
 Hispanic 3 6 9
 Others 2 1 3
Prior therapies
 Surgery 15 12 27
 Radiotherapy 23 28 51
 Chemotherapy 24 31 55
 Antiangiogenic 3 6 9
 Median regimen 2 2 2
 (range) (1–4) (1–4) (1–4)
Eastern cooperative oncology group performance status
0 8 7 15
1 14 17 31
2 2 7 9
Molecular profiles Aberrant/tested (%)
PIK3CA 3/22 (14) 14/29 (48) 17/51 (33)
PTEN 4/16 (25) 3/24 (13) 7/40 (18)
TP53 3/7 (43) 1/12 (8) 4/19 (21)
HER2 1/9 (11) 1/14 (7) 2/23 (9)
CKIT 0/11 (0) 2/18 (11) 2/29 (7)
(Continued)
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E542K and M1043I = 1, amplification = 1); 7 (18%) of 
40 tested patients with PTEN loss (n = 6) and/or mutation 
(R173C = 1); and 2 patients have both of PIK3CA 
mutation (E545K) and PTEN loss. Further analyses 
revealed that patients with squamous cell carcinomas were 
significantly younger and more likely to carry PIK3CA 
mutations than those with adenocarcinomas (p = 0.034 
per independent samples t-test for age and p = 0.016 per 
Fisher’s exact test for PIK3CA mutations, respectively). 
Approximately 20% (n = 11/55) and 36% (n = 4/11) of the 
referred patients received subsequent second- and third-
line phase I trial therapies.
Severe adverse events
All patients were included for analyses of SAEs; 
a total of 450 cycles of therapy were administered 
according to 38 phase I clinical trials [21]. During their 
first phase I trial therapy, approximately 20% of patients 
(n = 11/55) experienced 19 episodes of SAEs: neutropenia 
and thrombocytopenia (n = 5 each, 9%); hyponatremia 
(n = 2, 4%); and hypokalemia, hypomagnesaemia, 
hypophosphatemia, mucositis, fatigue, bowel perforation, 
and bacterial infection (n = 1 each, 2%). During the 
second phase I trial therapy, only 1 (9%) of 11 patients had 
an SAE (fatigue). Subsequently, no patient experienced 
an SAE before all 4 patients progressed within the initial 
8 weeks of their phase I trial therapy. In patients who 
received PI3K/AKT/mTOR pathway targeted therapeutic 
regimens, no apparent difference was observed between 
patients with PI3KCA mutation and/or PTEN loss/
mutation and those without.
Antitumor activity
The waterfall plot shown in Figure 1 demonstrates 
the best tumor response to their first-line phase I clinical 
trial therapy. Of 55 patients who received their first-
line phase I trial therapy (see Tables 2 and 3), 35% 
achieved SD ≥ 6 months/CR/PR (CR = 2, PR = 8, and 
SD ≥ 6 months = 9), and the median PFS in this group 
was 3.6 months (95% confidence interval [CI], 2.3–5; 
Figure 2A). Of 15 patients with PIK3CA mutations and/
or PTEN loss/mutations who received matched therapy, 
53% achieved SD ≥ 6 months/CR/PR (CR = 1, PR = 5 
and SD ≥ 6 months = 2), and the median PFS in this 
group was 6.0 months (95% CI, 3.2–8.8). These results 
compared favorably with nine patients who did not receive 
matched therapy targeting activated PI3K/AKT/mTOR 
pathway: 11.1% achieved PR (PR = 1; p = 0.08), and the 
median PFS in this group was 1.5 months (95% CI, 1.2–
1.8; p = 0.026; Figure 3A); as well as with seven patients 
without PIK3CA mutation and PTEN loss/mutations 
who received therapies targeting activated PI3K/AKT/
mTOR pathway: 14% achieved PR (PR = 1, p = 0.16) and 
the median PFS in this group was 1.5 months (95% CI, 
0.4 – 10.6; p = 0.06).
Of 11 patients who received their second phase I 
clinical trial therapy, 27% achieved SD ≥ 6 months/CR/
PR (PR = 1 and SD ≥ 6 months = 2), and the median 
PFS in this group was 4.2 months (95% CI, 3.0–5.4). Of 
4 patients who received their third phase I clinical trial 
therapy, no patient achieved SD ≥ 6 months/CR/PR.
Overall survivals
All patients were included in survival analyses. The 
median OS was 9.1 months (95% CI, 7.1–11.1 months; 
Figure 2A). Patients with metastatic or recurrent 
adenocarcinomas had a significantly greater median 
OS of 14.2 months (95% CI, 7.8–20.6) than those with 
squamous cell carcinomas (OS = 7.2 months; 95% CI, 
5.3–9.1; p = 0.001), as shown in Figure 2B. Patients 
with PIK3CA mutation and/or PTEN loss/mutation who 
received matched therapy, achieved a median OS of 
10.1 months (95% CI, 5.9–14.3), compared with those 
who did not (7.7 months; 95% CI, 1.6–13.8; p = 0.43; 
Figure 3B). Furthermore, patients with metastatic or 
Patient characteristics Adenocarcinoma Squamous cell carcinoma Total patients
(n = 24) (n = 31) (n = 55)
CMET 0/11 (0) 2/18 (11) 2/29 (7)
KRAS 3/19 (16) 0/26 (0) 3/45 (7)
ALK1 0/7 (0) 1/13 (8) 1/20 (5)
EGFR 1/16 (6) 0/22 (0) 1/38 (3)
BRAF 0/18 (0) 0/25 (0) 0/43 (0)
NRAS 0/13 (0) 0/18 (0) 0/31 (0)
AKT1 0/8 (0) 0/14 (0) 0/22 (0)
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Table 2: Clinical outcomes in patients with advanced squamous cell carcinoma of the cervix.
Age PIK3CA mutation PTEN loss 
or mutation
Best tumor 
response
PFS 
(months)
OS 
(months)
Matched 
therapy
Treatment
35 E542K ND -44% 9.7 10.1 Y Bevacizumab and 
Temsirolimus plus Doxil
37 E542K N -37% 10.3 10.3 Y A PI3K Inhibitor
37 E542K N -2% 4.2 6.4 Y Everolimus and Pazopanib
42 E542K N 21% 0.9 2.5 N Erlotinib and Praletrexate
59 E542K / M1043I N 50% 1.7 7.8 N Erlotinib and Praletrexate
35 E545K Y 0% 4.4 10.8 Y Bevacizumab and 
Temsirolimus plus Doxil
56 E545K P 8% 6.4 13.6 Y Sirolimus and Docetaxol
48 E545K ND -68% 32.6 40.3 Y Bevacizumab and 
Temsirolimus
40 E545K ND 7% 1.2 4.1 Y Bevacizumab and 
Temsirolimus plus Doxil
38 E545K N -1% 6.7 7.0 Y Bevacizumab and 
Temsirolimus plus Doxil
46 E545K N 10% 5.4 9.3 N Lenalidomide and 
Bevacizumab
48 E545K N 10% 3.5 9.4 N
HAI Abraxane and 
IV Gemcitabine plus 
Bevacizumab
62 E545K / D549H ND 21% 0.7 2.1 Y Bevacizumab and 
Temsirolimus plus Doxil
(Continued )
Figure 1: The waterfall plot shows the best tumor response to their initial phase I clinical trial therapy (n = 55).
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Age PIK3CA mutation PTEN loss 
or mutation
Best tumor 
response
PFS 
(months)
OS 
(months)
Matched 
therapy
Treatment
61 H1047R N 21% 1.3 1.3 Y A PI3K Inhibitor
28 N Y -42% 6.0 6.0 Y Bevacizumab and 
Temsirolimus plus Doxil
49 N Y -15% 2.6 3.5 N Bendamustine and 
Bevacizumab
62 N P 21% 2.4 2.5 N HAI Abraxane
36 N P 82% 1.5 7.7 N Bevacizumab and 
Temsirolimus plus Doxil
39 N P 21% 1.1 1.3 N A MEK Inhibitor and Docetaxol
41 N P 21% 0.4 1.1 N
Bevacizumab and 
Temsirolimus plus 
Carboplatin
34 N ND -43% 6.8 9.1 N Bevacizumab and 
Temsirolimus
25 N ND 14% 4.2 7.7 ? A PI3K Inhibitor and Carboplatin plus Paclitaxel
37 N ND -27% 1.4 10.9 ? Bevacizumab and 
Temsirolimus plus Doxil
43 N N 10% 7.9 12.4 N Erlotinib and Praletrexate
58 N N 16% 4.1 4.6 N Erlotinib and Praletrexate
29 N N 21% 2.7 4.2 N Bendamustine and 
Bevacizumab
69 N N 21% 1.2 1.7 N Erlotinib and Praletrexate
45 N N 21% 0.9 1.8 N HAI Oxaliplatin and PO Capecitabine
63 N N 21% 0.5 0.7 N Everolimus and Denosumab
48 ND P -21% 6.9 12.4 ? Bevacizumab and 
Temsirolimus plus Doxil
37 ND N 26% 2.3 7.2 N Trientine and Carboplatin
I, insufficient; N, no; ND, not done; OS, overall survival; P, partial loss; PFS, progression-free survival; Y, yes; +, censored; 
and ?, unknown.
recurrent squamous cell carcinomas who carried PIK3CA 
mutations (n = 14) achieved a median OS of 9.4 months 
(95% CI, 8.1–10.7), significantly longer than the median 
OS of those who did not carry PIK3CA mutations 
(n = 15; 4.2 months, 95% CI, 2.2–6.2; p = 0.019), as 
shown in Figure 4A. Patients with metastatic or recurrent 
adenocarcinomas who carried PIK3CA mutations (n = 3) 
achieved a median OS of 19.4 months (95% CI, 0 – 43.6), 
similar to those who did not carry PIK3CA mutations 
(n = 19; 14.2 months, 95% CI, 4.0–24.4; p = 0.75), as 
shown in Figure 4B. Patients with metastatic or recurrent 
PTEN-loss/mutation squamous cell carcinomas (n = 3) 
and adenocarcinomas (n = 4) achieved a median OS of 
6 months (95% CI, 2–10) and 11.3 months (95% CI, 
0–22.6), respectively, similar to the median OS of those 
with metastatic or recurrent PTEN-intact squamous cell 
carcinoma (n = 21; 7 months, 95% CI, 3.1–10.9; p = 0.76) 
and adenocarcinoma (n = 16; 15.7 months, 95% CI, 
7.1–24.3; p = 0.79), respectively (see Figure 5A and 5B).
DISCUSSION
In this study, we identified that patients with 
previously treated, locally advanced or metastatic cervical 
cancer harboring mutations in the PI3K/AKT/mTOR 
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Table 3: Clinical outcomes in patients with advanced adenocarcinoma of the cervix.
Age PIK3CA 
mutation
PTEN 
loss or 
mutation
Best 
tumor 
response
PFS 
(months)
OS 
(months)
Matched 
therapy
Treatment
55 Amplification P -100% 29.3 + 29.3 + Y Everolimus and Anastrozole
61 E545K Y -52% 18.7 19.4 Y Bevacizumab and 
Temsirolimus
51 H1047L N 21% 1.7 4.3 Y Sirolimus and Metformin
63 N Y -24% 1.7 7.9 Y Bevacizumab and 
Temsirolimus plus Doxil
41 N Y -11% 28.5 + 28.5 + N An Aurora Kinase Inhibitor
50 N R173C -6% 7.7 11.3 N Pazopanib and Pemetrexate
44 N P -21% 9.8 15.7 N A MEK Inhibitor and Docetaxol
62 N P 20% 2.1 19.7 N A Proteasome Inhibitor
43 N P -13% 40.4 + 40.4 + N A c-Met Inhibitor
51 N ND -21% 6.0 6.4 ? Bevacizumab and 
Temsirolimus
58 N ND 0% 5.7 7.9 ? Bevacizumab and 
Temsirolimus plus Doxil
27 N ND -29% 3.7 21.7 ? Bevacizumab and Cetuximab 
plus Erlotinib
46 N ND -16% 2.9 3.5 ? Bevacizumab and 
Temsirolimus plus Doxil
58 N ND 430% 2.5 20.8 ? Temsirolimus and Topotecan 
plus Bortezomib
63 N ND 21% 2.1 2.4 N Azacitidine and Oxaliplatin
44 N N -100% 18.9 28.7 + N An Aurora Kinase Inhibitor and Docetaxol
37 N N -64% 10.6 35.6 N A PI3K Inhibitor and Carboplatin plus Paclitaxel
59 N N 0% 3.7 5 + N Bevacizumab and VEGF Inhibition
57 N N -23% 3.2 14.2 N Bevacizumab and 
Temsirolimus
49 N N -5% 2.9 4.6 N An Aurora Kinase Inhibitor
41 N N 23% 2.8 8.2 N Bevacizumab and 
Temsirolimus plus Paclitaxel
60 N N 21% 0.7 2.1 N Bevacizumab and 
Temsirolimus plus Sorafenib
67 ND I 21% 3.6 10.7 + ? Everolimus and Anastrozole
40 ND I 21% 1.1 13.3 ? Bevacizumab and 
Temsirolimus plus Doxil
I, insufficient; N, no; ND, not done; OS, overall survival; P, partial loss; PFS, progression-free survival; Y, yes; +, censored; 
and ?, unknown.
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pathway achieved meaningful clinical benefit from a 
number of novel therapeutics administered in a phase I 
cancer center. Of particular interest were the objective 
responses, prolonged stable disease and PFS among these 
patients treated with PI3K/AKT/mTOR pathway targeted 
agents matching the somatic aberrations in this pathway. 
We conclude from these observations that targeted therapy 
among these patients with pathway potentiation is a viable 
strategy for further development.
Patients with metastatic or recurrent carcinoma of 
the cervix have limited therapeutic treatment options, 
particularly those in whom combination chemotherapy 
(without or with anti-angiogenesis agents) have been 
administered [11, 29, 30]. The Gynecologic Oncology 
Group (now NRG Oncology) developed phase II queues 
to explore chemotherapeutic (GOG 127 series, GOG 
128 series) and biological agents (GOG 227 series) in this 
setting. Reflecting the poor anticipated outcomes in these 
Figure 3: Kaplan-Meier plots for survivals. In Figure 3A, match therapy (in green) was associated with a median PFS of 6.0 months 
(n = 15; 95% CI, 3.2–8.8), significantly greater than non-matched therapy (in blue) with 1.5 months (n = 9; 95% CI, 1.2–1.8; p = 0.026). 
In Figure 3B, matched therapy (in green) was associated with a median OS of 10.1 months (n = 15; 95% CI, 5.9–14.3), compared to non-
matched therapy (in blue) with 7.7 months (n = 9; 95% CI, 1.6–13.8; p = 0.427).
Figure 2: Kaplan-Meier plots for survivals. In Figure 2A, a median OS of 9.1 months (95% CI, 7.1–11.1, in green) and a median PFS 
of 3.6 months (95% CI, 2.3–5.0, in blue) were observed in patients with metastatic or recurrent cervical carcinomas (n = 55). In Figure 2B, 
patients with adenocarcinoma (in green) showed a median OS of 14.2 months (n = 24; 95% CI, 7.8–20.6), significantly longer those with 
squamous cell carcinoma (in blue), 7.2 months (n = 31; 95% CI, 5.3–9.1; p = 0.001).
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patient cohorts, the statistical decision rules were powered 
to evaluate “inactive” therapy at  ≤ 15% for chemotherapy 
and ≤ 10% response and/or ≤ 10% non-progression at 
6 months, respectively. This provides context upon which 
to examine the findings in this study.
Several observations are of note. In general, patients 
with metastatic or recurrent squamous cell carcinoma 
of the cervix were significantly younger, and had a 
higher prevalence of PIK3CA mutations. However, they 
displayed lower antitumor activity to currently available 
phase I clinical trials at MD Anderson associated with 
significantly shorter OS than patients with metastatic or 
recurrent adenocarcinoma of the cervix. Second, matched 
therapy targeting the activated PI3K/AKT/mTOR pathway 
in patients with metastatic or recurrent squamous cell 
carcinoma of the cervix led to a favorably higher rate 
Figure 4: Kaplan-Meier plots for survivals. In Figure 4A for in patients with squamous cell carcinoma, PI3KCA mutations (in 
green) were associated with a median OS of 9.4 months (n = 14; 95% CI, 8.1–10.7), significantly longer than wild-type PI3KCA (in blue) 
with 4.2 months (n = 15; 95% CI, 2.2–6.2; p = 0.019). In Figure 4B for patients with adenocarcinoma, PI3KCA mutations (in green) were 
associated with a median OS of 19.4 months (n = 3; 95% CI, 0–43.6), compared to wild-type PI3KCA (in blue) with 14.2 months (n = 19; 
95% CI, 4–24.4; p = 0.754).
Figure 5: Kaplan-Meier plots for survivals. In Figure 5A for in patients with squamous cell carcinoma, PTEN aberrations (in green) 
were associated with a median OS of 6 months (n=3; 95% CI, 2–10), similar to PTEN intact (in blue) with 7 months (n = 21; 95% CI, 
3.1–10.9; p = 0.762). In Figure 5B for patients with adenocarcinoma, PTEN aberrations (in green) were associated with a median OS of 
11.3 months (n = 4; 95% CI, 0–22.6), similar to PTEN intact (in blue) with 15.7 months (n = 16; 95% CI, 7.1–24.3; p = 0.791).
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of SD ≥ 6 months/CR/PR as well as significantly longer 
PFS and OS than non-matched therapy. However, in 
patients with metastatic or recurrent adenocarcinoma 
of the cervix, there was no significant difference in OS 
associated with matched therapy in spite of a higher 
rate of SD ≥ 6 months/CR/PR and significantly longer 
PFS, which might be owing to at least three potential 
factors: lower prevalence of the activated PI3K/AKT/
mTOR pathway, intrinsic sensitivity to novel phase I 
trial therapy available at MD Anderson phase I service, 
and the presence of PIK3CA mutation and/or PTEN loss/
mutation that cannot stratify for aggressiveness of disease. 
Third, PIK3CA mutation, but not PTEN loss/mutation, 
was associated with significantly longer OS, indicating 
the differential effects of these genetic aberrations on 
sensitivity to matched therapy, as well as matched patients 
and the preferential choices of the treating physicians in 
the Phase I Clinical Trials Program, MD Anderson for 
assigning patients to matched therapy.
Of 136 patients with PIK3CA-mutation and/or 
PTEN-loss/mutation advanced solid tumors seen in our 
phase I clinic, 25% achieved SD ≥ 6 months/CR/PR 
(95%CI, 0.18–0.33) after receiving matched therapy 
targeting the activated PI3K/AKT/mTOR pathway, and 
a median PFS of 2.5 months (95% CI, 1.8–3.2) [31]. 
These outcomes were significantly lower than those 
reported in the current study of patients with PIK3CA-
mutation and/or PTEN-loss/mutation metastatic or 
recurrent carcinoma receiving matched therapy. Several 
confounding factors might have contributed to these 
differences. Almost half of the patients with metastatic 
or recurrent cervical carcinoma, especially those with 
squamous cell carcinoma, presented with PIK3CA 
mutation and/or PTEN loss/mutation, and this proportion 
was significantly higher in patients with advanced solid 
tumors (48% versus 22%, p = 0.002), suggesting that 
the activated PI3K/AKT/mTOR pathway is a driving 
mechanism for the survival of cervical carcinoma cells. 
Another factor is that concurrent mutations or specific 
molecular profiles might be more important than a single 
gene mutation. PIK3CA mutation was more prevalent in 
patients with KRAS mutation than in patients with wild-
type KRAS [31], whereas in this report, a low frequency 
of KRAS mutation was found in metastatic or recurrent 
cervical carcinomas, and in squamous cell carcinomas 
specifically, no KRAS mutation was identified in any of the 
26 tested patients (Table 1). Since PIK3CA mutation and/
or PTEN loss/mutation with simultaneous KRAS mutation 
were associated with significantly lower antitumor activity 
and shorter PFS than PIK3CA mutation and/or PTEN 
loss/mutation without simultaneous KRAS mutation, two 
or more coexisting mutations constitute different classes 
of mutation profiles that predict responses to various 
biologically targeting agents and/or their combinations 
and render matched therapy more complicated than 
expected. When developing efficacious regimens to target 
the activated PI3K/AKT/mTOR pathway, metastatic or 
recurrent squamous cell carcinomas of the cervix might 
be an appropriate clinical model to be tested in early-phase 
clinical trials because of their high prevalence of PIK3CA 
mutation and/or PTEN loss/mutation as previously 
reported [15, 32–35] and their lack of simultaneous KRAS 
mutation, in agreement with the hypothesis that coexisting 
KRAS mutation become resistant to regimens targeting the 
activated PI3K/AKT/mTOR pathway.
When considering the clinical relevance of our 
findings, several limitations should be kept in mind. 
First, matched therapy includes not only phase I clinical 
trials of a single agent targeting the activated PI3K/
AKT/mTOR pathway, but also phase I clinical trials 
of an agent targeting this pathway in combination with 
other biologically targeted agents or conventional 
chemotherapeutic agents. The importance of using an 
agent to target the activated PI3K/AKT/mTOR pathway 
might be overestimated since tumor control might be 
induced by simultaneous inhibition of other key targets 
and/or processes by the combination regimens. Second, 
patients with poor clinical outcomes may have been 
selectively excluded from being referred to a phase I trial 
because of rapid tumor progression, poor performance 
status, insufficient organ function, severe comorbidity, 
economic issues, and inaccessibility of treatment. Third, 
molecular studies of mutation profiles were usually 
conducted on archival tumor specimens whenever 
available, regardless of whether the specimens had been 
treated in a phase I clinical trial. Finally, we had a limited 
sample size available for subgroup analyses, which 
confounded the ability to validate statistical significance 
in category assessment. Therefore, conclusions from this 
retrospective study should be considered preliminary 
evidence to generate hypotheses, which require further 
validation in larger prospective studies.
In conclusion, our results showed that almost half 
of the patients with metastatic or recurrent squamous cell 
carcinoma of the cervix had PIK3CA mutation and/or 
PTEN loss/mutation without coexisting KRAS mutation, 
providing an appropriate patient population to the test 
efficacy of a regimen including a single agent targeting 
the PI3K/AKT/mTOR pathway or a combination regimen 
with either another biologically targeted agent and/or 
conventional chemotherapeutic agent. Matched therapy 
targeting a specific mutation has provided apparent 
clinical benefits for cancer patients. Complicated mutation 
profiles might be more important and useful than a single 
gene mutation in predicting antitumor activity and clinical 
efficacy to a specific regimen [36–40]. Therefore, future 
development and evaluation of novel regimens targeting 
the activated PI3K/AKT/mTOR pathway for the purpose 
of translating high antitumor activity to prolonged survival 
benefit is warranted in larger prospective clinical trials for 
the treatment cervical carcinoma, especially squamous cell 
carcinoma.
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